SEOM‑GEMCAD‑TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023)

• Fernando Rivera ^[1] ; Federico Longo ^[2] ; Marta Martín Richard ^[9] ; Paula Richart ^[10] ; Maria Alsina ^[3] ; Alberto Carmona ^[4] ; Ana Belén Custodio ^[5] ; Ana Fernández Montes ^[6] ; Javier Gallego ^[7] ; Tania Fleitas Kanonnikof ^[8]
  1. [1] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  2. [2] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  3. [3] Hospital Universitario de Navarra

     Hospital Universitario de Navarra

     Pamplona, España

     
  4. [4] Hospital Morales Meseguer

     Hospital Morales Meseguer

     Murcia, España

     
  5. [5] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  6. [6] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  7. [7] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  8. [8] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  9. [9] Medical Oncology Department, ICO Duran i Reynals, Barcelona, Spain
  10. [10] Medical Oncology Department, Hospital La Fe, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2826-2840
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Gastric cancer (GC) is the ffth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profle patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation+surgery+adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the diferent evidences and recommendations based on the literature.